NAV3 Is a Novel Prognostic Biomarker Affecting the Immune Status of the Tumor Microenvironment in Colorectal Cancer

Figure 5

The expression of NAV3 and its clinical significance in CRC. (a) The expression of NAV3 was distinctly downregulated in CRC specimens. (b, c) The expressions of NAV3 in groups which were divided by age and gender. (d) Higher levels of NAV3 were observed in CRC specimens at different stages. (e) Kaplan-Meier curves estimating the overall survival according to the expression of NAV3 in patients with CRC.

(a)

(b)

(c)

(d)

(e)